Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAPI-GO
- Development stage
- Unknown
- Lead developer
- SOFIE
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FAPI-GO is a fibroblast activation protein (FAP)-targeted radiopharmaceutical developed by SOFIE. It is designed to bind specifically to FAP, an enzyme highly expressed on cancer-associated fibroblasts (CAFs) within the tumor stroma of various solid tumors, including gastroesophageal cancers. By targeting the tumor microenvironment rather than the malignant cells themselves, FAPI-GO facilitates the delivery of a radioactive payload directly to FAP-expressing tissues. The agent is currently in Phase 3 clinical development for applications in gastroesophageal cancers, where it is being evaluated for its potential in targeted imaging or therapy within the itheranostics framework.
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on FAPI-GO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAPI-GO.